MLLT1
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MLLT1, super elongation complex subunit | MIM:159556 | Ensembl:ENSG00000130382 | HGNC:HGNC:7134 | PA30848 | 19p13.3 |
Gene Categories:
KINASEGO terms in MLLT1
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | TAS | GO:0003677 | DNA binding |
| MF | IPI | GO:0005515 | protein binding |
| CC | IDA | GO:0001650 | fibrillar center |
| CC | TAS | GO:0005634 | nucleus |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005829 | cytosol |
| CC | IDA | GO:0008023 | transcription elongation factor complex |
| BP | IEA | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | TAS | GO:0006366 | transcription by RNA polymerase II |
| BP | TAS | GO:0006368 | transcription elongation from RNA polymerase II promoter |
| BP | IEA | GO:0006469 | negative regulation of protein kinase activity |
Gene expression in normal tissue: MLLT1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MLLT1
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| kegg | hsa05202 | Transcriptional misregulation in cancer - Homo sapiens (human) |
| reactome | R-HSA-112382 | Formation of RNA Pol II elongation complex |
| reactome | R-HSA-674695 | RNA Polymerase II Pre-transcription Events |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-75955 | RNA Polymerase II Transcription Elongation |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD345 | Compound 10b [PMID: 11504634] | 5 |
| iGMDRD150 | RITA | 2 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD512 | nutlin 3 | 4 |
| iGMDRD48 | Dexamethasone | 3 |
| iGMDRD945 | ML214 | 3 |
| iGMDRD177 | Teniposide | 2 |
| iGMDRD77 | Itraconazole | 5 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD415 | LE-135 | 2 |
| iGMDRD289 | Parthenolide | 1 |
| iGMDRD137 | Indisulam | 2 |
| iGMDRD886 | Compound 1541A | 3 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD871 | BRD6368 | 3 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD420 | Leucascandrolide A | 3 |
| iGMDRD126 | Tipifarnib | 2 |
| iGMDRD634 | SCHEMBL2608041 | 7 |
| iGMDRD375 | GW-405833 | 2 |
| iGMDRD679 | Bistramide A | 3 |
| iGMDRD280 | CYTOCHALASIN B | 3 |
| iGMDRD294 | Batimastat | 1 |
| iGMDRD885 | Compound 110 | 2 |
| iGMDRD782 | DC-45-A2 | 2 |
| iGMDRD171 | Pemetrexed | 2 |
| iGMDRD255 | SB225002 | 5 |
| iGMDRD524 | ISX-9 | 2 |
| iGMDRD23 | Gossypol | 6 |
| iGMDRD60 | Quinoclamine | 9 |
| iGMDRD577 | BIX01294 | 12 |
| iGMDRD887 | Compound 23 citrate | 3 |
| iGMDRD730 | Kahalalide F | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MLLT1
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.